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T oeval uat ethepossib lee ﬀects ofLMP2A (EBVlatent membraneprotein 2A)onhuman gastriccancer cell lineSGC-7901, LMP2A
coding gene was subcloned into shuttle plasmid pAdTrackCMV to form transfer plasmid pAdTrackCMV-2A, which was linearized
with PmeI and cotransformed into E.coli BJ5183 with adenovirus genomic plasmid of pAdeasy-1. The identiﬁed recombinant
adenovirusplasmidDNAwasdigestedwithPacIandtransfectedinto293cellstopackagerecombinantadenovirusparticlesnamed
vAd-2A. Then the expression and antiapoptosis activities of LMP2A on SGC-7901 infected with vAd-2A were analyzed. The vAd-
2A was successfully constructed and identiﬁed by PCR, restriction digestion, and sequencing. LMP2A expression in SGC was
identiﬁed by strong green ﬂuorescence expression with ﬂuorescence microscopic photograph and Southern blotting. The growth
of LMP2A expressing SGC cells was apparently improved. Both cyclin E expression and S phase ratio in LMP2A expressing SGC
cells were upregulated by cell cycle analysis and confocal microscopic analysis respectively. The replication-deﬁcient recombinant
adenovirus vector can express LMP2A antigen in SGC cells and inhibit their apoptosis. The results indicate that LMP2A might
play an important role in pathogenesis of EBV-associated gastric cancer (EBVaGC). This study establishes a foundation for further
study on EBVaGC and its gene therapy.
1.Introduction
Epstein-Barr virus (EBV), a gamma herpes virus, has been
associated with a variety of human malignancies such
as Burkitt’s lymphoma (BL), nasopharyngeal carcinoma
(NPC), and gastric cancer (GC) [1] .E B Vi sd e t e c t e di nt h e
tissue of about 10% of gastric carcinoma cases throughout
the world [2, 3]; furthermore, EBV is associated with 80%–
100% of the rare lymphoepithelioma-like gastric carcinomas
[4] and is also present in 35% of gastric stump carcinomas
[5]. Latent membrane protein 2A (LMP2A) is an EBV-
encoded protein that has been implicated in regulating viral
latency and pathogenesis within infected cells [6]. Recent
studiesrevealedthatabout50%EBV-associatedgastriccarci-
noma (EBVaGC) expressed LMP2A. Gastric cancer is one of
the most common malignant tumors in the world. It is very
diﬃcult to remove and eliminate tumor cells completely by
surgical, radio therapeutic, and chemotherapeutic methods.
Therefore, developing an immunotherapeutic method to
treatgastriccancerisofcriticalimportance.LMP2Acontains
many potential T-cell activating epitopes which can trigger
c yt o t o x i cTl ym p h o c yt e s( C T L ) ,t h u si ti sa ni d e a lt a r g e tg e n e
of immunotherapy. However, the pathogenic role of LMP2A
in tumor progression is not well understood. So making
an intensive study of LMP2A is of important meaning to
reveal the disease mechanism of EBV. In the present study,
LMP2A gene was cloned into adenoviral vector to generate
recombinant adenovirus, which could introduce LMP2A
geneintogastriccancercells,inordertoevaluatethepossible
eﬀects of LMP2A expression on human gastric cancer cell
line. Our study provides more complete understanding of
the role of LMP2A in EBV latency and tumorigenesis and
establishes a foundation for further study on gastric cancer
and its gene therapy.2 Gastroenterology Research and Practice
2.MaterialsandMethods
2.1. Cell Culture and Medium. Type 1 EBV strain positive
B95-8 cells were used for amplifying LMP2A gene, and
human embryonic kidney cell line HEK293 were used for
packing recombinant adenovirus. The human GC cell line
SGC-7901 was purchased from ATCC. All cell lines were
maintained in high glucose DMEM medium supplemented
with 100mL/L fetal bovine serum (FBS). The culture
medium contained 100U/mL of penicillin and 100μg/mL of
streptomycin(GIBCOBRL,Gathersburg,Md)at37◦Cin5%
CO2.
2.2. Target Gene and Primers. The RT-PCR product of
LMP2A was obtained from B95-8 cell line genome RNA.
The speciﬁc primers were as follows: 5 -GGCAGATCTATG-
GGGTCCCTAGAAATGGTG-3  (sense strand) and 5 -
GCGATATCTTATACAGTGTTGCGATATGG-3  (antisense
strand),andBglIIandEcoRVrestrictionsitesandprotective
bases were introduced into sense and antisense primers,
respectively, as underlined. The predicted length of PCR
product is about 1500bp.
2.3.RecombinantRetroviralVectorConstruction. PCRampli-
ﬁed target gene LMP2A and shuttle vector pAdTrack-
CMV were digested with Bgl II and EcoR V. The digested
products were puriﬁed and ligated with DNA ligation I to
form transfer plasmid of pAdTrackCMV-2A. Then it was
linearized by PmeI and cotransformed into BJ5183 bacterial
cells with adenovirus genomic DNA plasmid of pAdeasy-
1. The homologous recombinant adenoviral plasmid named
pAd-2A was conﬁrmed by PCR, restriction endonuclease
analyses and sequencing. The control retroviral vector pAd-
LacZ was constructed in the same manner.
2.4. Production and Propagation of Recombinant Adenoviruses
in HEK293. Four micrograms of recombinant adenoviral
vector DNA, after Pac I digestion and ethanol precipitation,
were transfected into HEK293 cells in each 25cm2 ﬂask
at 50%–70% conﬂuence. Transfection was accomplished
using the LipofectAMINE reagent from Life Technologies
(Gaithersberg, Md). Transfected cells were monitored for
GFP expression and collected 7–10 days after transfection,
when about 1/3 cells appeared cytopathic eﬀect (CPE), by
scraping cells oﬀ ﬂasks and pelleting them along with any
ﬂoating cells in the culture. After centrifugation, the cell
pellet was resuspended in 2.0mL sterile phosphate-buﬀered
saline (PBS) and lysed for four consecutive freeze/thaw
cycles,and the virus was collectedfrom the supernatant.One
t h i r do fv i r a ll y s a t ew a su s e dt oi n f e c tH E K 2 9 3c e l l si na
25cm2 ﬂask. The infection eﬃciency could be conveniently
followed with green ﬂuorescent protein (GFP). Three to
four days later, viruses were harvested as described above.
This process was repeated 1–3 times. At this point, viral
titers were often high enough to use for gene transfer
experiments in cultured cells. Viral titer was determined by
virus titer determination kit following the manufacturers
recommendations (Ben Yuan Zheng Yang Company, Beijing,
China), which was up to 3.16 × 109 pfu/mL.
2.5. Infection of SGC Cells with Recombinant Adenoviruses.
When cultures of SGC cells were 70% conﬂuence, the
cells were incubated with recombinant adenoviruses at a
proper MOI at 37◦C overnight. The cells then were washed
once with PBS, and fresh medium was added. At 4 days
after infection, the infection eﬃciency was estimated by
using ﬂuorescence microscopy to detect GFP-expression.
The infected SGC cells were harvested, and transcriptional
expression of LMP2A in SGC cells were examined by RT-
PCR followed by Southern blot analysis.
2.6. MTT. Cell viability was assayed by the incorporation
of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrasodium
bromide (MTT) dye (Sigma). SGC cells were washed with
PBS and seed into 96-well plates at 4 × 103 cells/10μLp e r
well.Usedproperamountofvirusthatminimizecytotoxicity
infect the cells after their adherence. Following 1h of serum
starvation incubated with TGF-β1 (10ng/mL), 100μLo f
MTT solution (5mg/mL) was added to each well after 0, 24,
48, 72, 96, 120h of incubation, respectively, and the plates
were incubated for 4h at 37◦C. Then, 100μLD M S Ow a s
added to the wells, and the plates were incubated for 10min
at 37◦C. The absorbance (A) was measured at 490nm with a
microplatereader(SPECTRAMAX190;MolecularDevices).
2.7. RT-PCR and Southern Blot Analysis. Total RNA was
extracted using Trizol RNA isolation reagent (Molecular
Research Center, Cincinnati, Ohio). 1μgo ft o t a lR N A
was transcribed using the Reverse Transcription System
(Promega, USA). Total RNA was treated with DNase
I (Roche, Basel, Switzerland) to remove contaminating
genomic and adenoviral DNA before cDNA was prepared.
Three microliters of cDNA for each sample were used
to perform the PCR. PCR on total RNA (before reverse
transcription) was used to control for DNA contamination
in samples. The sequences of primers were as follows:
5 -ATGACTCATCTCAACACATA-3  (nt. 166874-166893),
5 -CATGTTAGGCAAATTGCAA-3  (nt. 166380-166361).
Product size was 280bp. As probe, the oligonucleotide:
ATCCAGTATGCCTGCCTGTA (nt. 166862-166881) was
used. Southern blot hybridization was performed after
RT-PCR for conﬁrmation. The ampliﬁed products were
electrophoresed in 2% agarose gel, transferred onto a
Hybond N+ nylonmembrane(AmershamPharmaciaBiotec,
Ireland), and subjected to hybridization with 3 -end-DIG-
labeled oligonucleotide probes. The hybridized signals were
detected by alkaline phosphatase (AP) conjugated anti-
DIG antibodies. The substrate of AP was CSPD (Roche
Diagnostics, Germany). cDNAs from EBV immortalized
lymphoblastoid cell lines (LCL) were used as positive con-
trols, and those from EBV-negative SGC cells as negative
controls.
2.8. Cell Cycle Analysis by Flow Cytometry. For ﬂow cytom-
etry analysis of the DNA content, SGC cells infected withGastroenterology Research and Practice 3
Table 1: Antiapoptosis activity of LMP2A on SGC cells.
Cell lines A (means ± SD) and antiapoptosis ratio (%)
0h 24h 48h 72h 96h 120h
SGC cells-LMP2A 0.179 ± 0.020 0.352 ± 0.006 0.51 ± 0.015 0.731 ± 0.014 0.743 ± 0.007 0.63 ± 0.022
−1.105%∗ 23.944% 21.513% 20.826% 24.874% 16.029%
SGC cells-vect 0.175 ± 0.017 0.290 ± 0.023 0.42 ± 0.019 0.588 ± 0.016 0.577 ± 0.018 0.52 ± 0.013
−3.315% 2.112% 0.946% −2.810% −3.025% −3.643%
SGC cells 0.181 ± 0.032 0.284 ± 0.012 0.42 ± 0.013 0.605 ± 0.028 0.595 ± 0.021 0.54 ± 0.027
100% 100% 100% 100% 100% 100%
vAd-2A, vAd-LacZ 24h or 48h after infection, or parental
cells (more than 106 cells) in either suspension or adhesion,
were harvested and ﬁxed in 70% ethanol for 3h. The
ﬁxed cells were washed once with PBS and resuspended in
PBS containing 10μg/mL DNase-free RNase and 25μg/mL
propidium iodide. DNA ﬂuorescence was measured using a
Coulter EPICS Proﬁle II ﬂow cytometer equipped with an
argon laser to give 488nm light. Data from 104 cells were
collected, and the percentages of cells in the S phase of the
c e l lc y c l ew e r ed e t e r m i n e db yM u l t i c y c l es o f t w a r e( P h o e n i x
FlowSystems).Analysiswasrepeatedthreetimesforeachcell
group.
2.9.ConfocalLaserScanningMicroscopy. Forconfocalmicro-
scopic analysis, cover slips containing indicated adenovirus
infected SGC cells were washed twice with PBS and ﬁxed
with paraformaldehyde (4% in PBS) for 30min. Fixation
was stopped by incubation in glycine (0.1M in PBS) for
10min, and the cells were permeabilized with Triton X-
100 (0.3% in PBS) for 30min. Free binding sites were
saturated with 1% bovine serum albumin solution for 1h
at room temperature and then incubated with primary
antibody (rabbit monoclonal anticycinE, diluted 1:200 in
PBS). After incubation for 1h at 37◦C, the cells were washed
3 times with PBS and then incubated for 1h at 37◦Cw i t h
the secondary antibody (Rhodamine-conjugated Aﬃnipure
Goat AntiMouse IgG, 1:200 dilutions). Immunoﬂuores-
cence and direct ﬂuorescence (EGFP) images were taken
using a confocal microscope (Zeiss).
2.10. Statistics Analysis. All data are expressed as means ±
SD. Statistical comparisons were made using the analysis of
variance. P<0.05 was considered signiﬁcant.
3. Results
3.1.AnalysisofRecombinantPlasmidpAd-2A. Thefragments
of PCR ampliﬁcation and Pac I digestion of plasmid pAd-
2A digested were 1500bp, 37.58kb, and 3.0kb, respectively
(Figure 1). All the products were detected by 1% agarose gel
electrophoresis as predicted. The expression of the LMP2A
gene was veriﬁed by gene sequencing.
3.2. Preparation of Recombinant Adenovirus. Expression was
visible 24h after transfection in 20%–30% of the cells, repre-
senting the fraction of the population that was transfected.
15000bp
5000bp
2500bp
1000bp
250bp
1545bp
123 4 56
37.58kb
3kb
Figure 1: Restrictive analysis of pAd-2A with Pac I and PCR
product of target gene. lane 1: Marker DL15000; lane 2: PCR
product of positive control (EBV positive B95-8 cell); lane 3: PCR
product of pAd-2A; lane 4: pAd-2A/Pac I; lane 5: pAd-2A; lane 6:
PCR product of pAd-GFP.
Comet-like foci, visualized with GFP ﬂuorescence, began
to appear at 4-5 days after transfection, indicating aden-
oviruswasproducedsuccessfully(Figure 2).Theadenovirus-
mediated gene LMP2A expression was veriﬁed in HEK 293
by RT-PCR. The expected 1500-bp fragment was ampliﬁed
from pAd-2A transfected SGC cells, but not from pAd-LacZ
transfected cells (Figure 3).
3.3. Transcriptional Expression of LMP2A in SGC Cells. GFP
expression was visualized by ﬂuorescence microscopy 48h
after transfection, and the infection rate can reach up to 90%
4 days postinfection, indicating vAd-2A could eﬀectively
infectSGCcells(Figure 4).TotalRNAwasextractedfromthe
test and control cells, and LMP2A-speciﬁc primers were used
for ampliﬁcation by RT-PCR. PCR products were hybridized
by Southern blotting analysis with a LMP2A-speciﬁc probe.
The expected 280-bp fragment was ampliﬁed from vAd-2A-
infected SGC cells, but not from parental and vector control
SGC cells (Figure 5). The expression of LMP2A protein
in vAd-2A-infected SGC cells was also veriﬁed by Western
blotting (Figure 6).
3.4. MTT. T h ec e l lg r o w t hw a sa n a l y z e db yM T Ta s s a y .T h e
viable cell number of vAd-2A-infected SGC cells increased
signiﬁcantly (P<0.05) compared with SGC cells at the same4 Gastroenterology Research and Practice
(a) (b)
Figure 2: Adenovirus-producing foci after transfection of 293 cells, (a) 2 days after transfection; (b) 7 days after transfection (CPE).
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Figure 3: Transcriptional expression of LMP2A in pAd-2A trans-
fected 293 cells. Lane 1: Marker DL2000; lane 2: positive control
(EBV-positive LCL); lane 3: pAd-2A transfected; lane 4: pAd-LacZ
transfected; lane 5: negative control (PCR on total RNA without
reverse transcription).
Figure 4: GFP expression in target cells infected with vAd-2A.
time point, the antiapoptosis ratio in 0h, 24h, 48h, 72h,
96h, and 120h is −1.105%, 23.944%, 21.513%, 20.826%,
24.874%,and16.029%,respectively,asshowninTable 1.vA d
infected SGC cells had no signiﬁcant change.
3.5. LMP2A Increased the Level of Cyclin E. The infection
r a t e so fv A da n dv A d - 2 A - i n f e c t e dS G Cc e l l sw e r eb o t ha b o u t
80% after 48h infection visualized with GFP ﬂuorescence (b,
c )w h i l en oG F Pw a sv i s u a l i z e di nS G Cc e l l s( a ) ,a ss h o w n
123 4 5 6
Figure 5: Detection of LMP2A expression in SGC cells by PCR-
Southern blotting. Lane 1: DIG-labeled DNA molecular weight
marker VIII (Roche); lane2: SGC cells; lane 3: vAd infected SGC
cells; lane 4: negative control (PCR on total RNA without reverse
transcription); lane 5: vAd-2A-infected SGC cells; lane 6: positive
control (EBV-positive LCL).
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Figure 6: The expression of LMP2A protein in vAd-2A-infected
SGC cells by Western Blotting β-actin was used for internal control,
lane 1, 2, 3: vAd-2A-infected SGC cells; lane 4: vector control (SGC-
GFP).
in Figure 7. The level of cyclin E in vAd-2A-infected SGC
cells increased signiﬁcantly, and almost all of the infected
cells could express cyclin E (f). These results suggested that
LMP2AcouldenhancetheexpressionofcyclinEinSGCcells
signiﬁcantly.
3.6. The LMP2A-Positive SGC Cells Have an Increased Num-
ber of Cells in S Phase. The percentage of LMP2A-positive
and LMP2A-negative cells in S phase of the cell cycle is
shown in Table 2. The data showed a signiﬁcant increase in
the percentage of G1-phase-arrested cells in SGC cells after
transduction with an adenovirus carrying LMP2A gene in
comparison with parental and vector control SGC cells (P<
0.01).Gastroenterology Research and Practice 5
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Figure 7: Confocal analysis for cyclin E on SGC cells.
Table 2: Inﬂuence of LMP2A expression on cell cycle (FCM
analysis) (means ± Std).
Cell lines S phase (%)
24h 48h
SGC cells 13.227 ± 4.552 12.53 ± 3.206
SGC cells-LMP2A 14.035 ± 3.371 12.891 ± 2.613
SGC cells-vect 35.152 ± 5.109∗ 25.593 ± 4.056∗∗
∗F = 23.9048, P=0.0014 < 0.01, ∗∗F = 14.8453, P=0.0048 < 0.01, SGC-
LMP2A versus SGC or SGC-vect.
4. Discussion
Gastric cancer, with clinical prognosis, is the second leading
cause of cancer-related mortality worldwide [7]. Recently,
great attention has been paid to the association of EBV
infection and gastric carcinoma. EBV is detected in the
tissue of about 10% of gastric carcinoma cases throughout
the world. In each case, 100% of carcinoma cells are
infected with EBV. Analysis of EBV in carcinoma biopsies
indicates that carcinoma is formed by the proliferation of
a single EBV-infected cell [2]. These ﬁndings suggest that
EBV plays an important role in the development of EBV-
positive gastric carcinomas. LMP2A gene is expressed in
vivo in humans with latent infections and most EBV-related
malignancies [8–11]. Recent studies revealed that about
50% EBV-associated gastric carcinoma (EBVaGC) expressed
LMP2A.Duetothispersistentexpression,LMP2Aisthought
to play an important role in EBV latency and may be an
important risk factor in EBV-associated diseases.
It has been reported that LMP2A is involved in blocking
B-cell speciﬁc signaling pathways and calcium mobilization,
whichmightbeadvantageousformaintaininglatentpatterns
of EBV infection and inhibiting EBV reactivation [12].
LMP2A is also reported to transform epithelial cells, greatly
aﬀect cell growth and diﬀerentiation pathways in a human
keratinocyte cell line (HaCaT), and inhibit transforming
growth factor-β1-induced apoptosis in HSC-39, through
activation of the phosphatidylinositol-3-kinase (PI3K)-Akt
pathway [13, 14]. EBV latent membrane protein 2A activates
beta-catenin signaling in epithelial cells [15]. The emerging
importance role of LMP2A in both B-cell and epithelial cell
growth led us to evaluate the eﬀect of LMP2A on cell cycle
regulation in a GC cell line. TGF-β is a multifunctional
cytokine that plays important roles in regulating cell growth
and diﬀerentiation in many biological systems [16]. TGF-β
can induce immunoglobulin A class switching and play an
important role in diﬀerentiation, growth, matrix formation,
and the regulation of immune and inﬂammatory responses
[17, 18]. It is an inducer of apoptosis in BL and some
gastric carcinoma cell lines [19–22]. Makoto Fukuda et al.
demonstrated that LMP2A eﬀectively suppressed TGF-β1-
induced apoptotic death of B cells and gastric carcinoma
cells, and the antiapoptosis eﬀect was not mediated through
decreased expression of TGF-β receptors. In our study, the
data of MTT showed the viable cell number of vAd-2A-
infected SGC cells increased signiﬁcantly, compared with
parental SGC cells at the same time point. The antiapoptosis
ratio of vAd-2A-infected SGC cells in 0h, 24h, 48h, 72h,6 Gastroenterology Research and Practice
96h and 120h is −1.105%, 23.944%, 21.513%, 20.826%,
24.874% and 16.029%, respectively. In accordance with
Makoto Fukuda et al., this result proved the antiapoptosis
activities of LMP2A on SGC cells.
Abnormalities in cell cycle regulation lead to uncon-
trolled cell proliferation and the transformation into cancer
cells [23, 24]. Cell cycle analysis indicated that vAd-2A-
infected SGC cells had signiﬁcantly more cells in S phase
in comparison with parental and vector control SGC cells.
Cyclins, CDKs, and CDKIs play important roles in control-
ling major checkpoints in the mammalian cell cycle [25].
Cyclin E overexpression occurred in 50%–60% of GC and
adenocarcinomas [26] and is essential for progression from
early to late G1 [27]. The cyclin E expressions of SGC
detected by confocal microscopic analysis showed a positive
linear correlation with S phase. Liang Bin et al. analyzed
the relationship between cyclin E/CDK2 expression and
clinicopathological characteristics of the tumors, indicating
that overexpression of cyclin E protein was correlated with
poorerdiﬀerentiationadvancedtumorstageandlymphnode
involvement [28], which was consistent with the report of
Sakagnchi et a1. [29].
In summary, these results suggest that upregulated
expression of cyclin E and S phases caused by LMP2A may
beassociatedwiththemalignantpotentialingastriccanceras
well as potentiate metastases. LMP2A could increase GC cell
proliferation via upregulating the expression of cyclin E and
CDK2 which induced S phase arrest and inhibit apoptosis
of SGC cells. These studies have provided a more complete
understanding of the role of LMP2A in tumorigenesis of GC
and established a foundation for further study on gastric
cancer and its gene therapy.
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